絞り込み

16738

広告

Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.

著者 Reiman EM , Arboleda-Velasquez JF , Quiroz YT , Huentelman MJ , Beach TG , Caselli RJ , Chen Y , Su Y , Myers AJ , Hardy J , Paul Vonsattel J , Younkin SG , Bennett DA , De Jager PL , Larson EB , Crane PK , Keene CD , Kamboh MI , Kofler JK , Duque L , Gil
Nat Commun.2020 Feb 03 ; 11(1):667.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Miscellaneous

Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer's dementia, while the APOE2 allele is associated with a lower risk of Alzheimer's dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer's dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer's dementia cases and controls. APOE2/2 was associated with a low Alzheimer's dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer's disease could have a major impact on the understanding, treatment and prevention of the disease.
PMID: 32015339 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード